Terminated PHASE1 INTERVENTIONAL 4-arm NCT01483183

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation (CADENCE 215)

A Multi-center, Parallel-group, Double-blind, Placebo-controlled, Randomized, Ascending Dose Trial to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Infusions of OPC-108459 Administered to Subjects With Paroxysmal and Persistent Atrial Fibrillation

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions Atrial Fibrillation Paroxysmal Atrial Fibrillation Persistent Atrial Fibrillation

Interventions OPC-108459 Placebo

Updated 9 times since 2017 Last updated: Feb 24, 2017 Started: Nov 30, 2011 Primary completion: Oct 31, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Enrollment Difficulty

Other terminated trials from Otsuka Pharmaceutical Development & Commercialization, Inc.

More terminations from Otsuka Pharmaceutical Development & Commercialization, Inc.

Other Atrial Fibrillation trials with similar outcome

Browse all Atrial Fibrillation trials

A PHASE1 clinical study on Atrial Fibrillation and Paroxysmal Atrial Fibrillation, this trial is terminated or withdrawn. The trial is conducted by Otsuka Pharmaceutical Development & Commercialization, Inc. and has accumulated 9 data snapshots since 2011. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE1

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
May 2017 — Jun 2018 [monthly]

Terminated PHASE1
Feb 2017 — May 2017 [monthly]

Terminated PHASE1
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Data source: Otsuka Pharmaceutical Development & Commercialization, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Ancona, Italy , Barcelona, Spain , Berlin, Germany , Bologna, Italy , Chertsey, United Kingdom , Cremona, Italy , Fuenlabrada, Spain , Germantown, United States , Granada, Spain and 14 more locations